Absci Corporation (Nasdaq: ABSI), a pioneering name in the realm of generative AI drug creation, has announced its participation in two notable investor conferences, offering an exciting platform for dialogue and engagement with potential investors and industry stakeholders. The conferences will spotlight Absci's innovative approach to drug development, emphasizing its Integrated Drug Creation™ platform.

2. Conference Highlights

H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Absci will participate in the H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference, with a fireside chat scheduled for Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. This conference is anticipated to attract a diverse audience interested in the intersection of artificial intelligence and drug discovery, and Absci's contribution is expected to be a highlight.

24th Annual Needham Virtual Healthcare Conference

Following its appearance at the H.C. Wainwright Conference, Absci will also feature in the 24th Annual Needham Virtual Healthcare Conference. The fireside chat for this event is set for Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time. This conference will provide another significant opportunity for Absci to discuss its advancements and strategies in the healthcare sector, particularly in the context of biopharmaceutical innovations.

3. Accessing the Webcasts

For those interested in following these discussions, live and archived webcasts of the fireside chat sessions will be accessible on Absci's investor relations website at investors.absci.com. This accessibility allows for a wider audience to engage with Absci's vision and technological advancements, even if unable to attend the events live.

4. About Absci Corporation

Absci is at the forefront of integrating artificial intelligence with scalable wet lab technologies to revolutionize drug creation. The company’s Integrated Drug Creation™ platform is designed to expedite the journey from drug conception to clinical application, enhancing the probability of success by optimizing various drug characteristics concurrently. Absci’s capabilities allow for the screening of billions of cells weekly, transforming AI-designed candidates into wet lab-validated candidates within a remarkably short timeframe of six weeks.

With its headquarters in Vancouver, Washington, Absci also operates an AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. This global presence underscores Absci's commitment to harnessing cutting-edge technology for the development of biopharmaceuticals that can improve patient outcomes.

5. Conclusion

Absci Corporation's participation in the upcoming investor conferences signals its proactive approach in engaging the investment community and sharing its innovative advancements in drug development. As the company continues to push the boundaries of what is possible through AI-driven solutions, both investors and industry observers will be keenly watching to see how Absci leverages these platforms to further its mission of creating better biologics, faster.

Original press release